pulmonary alveolar proteinosis
Information
- Disease name
- pulmonary alveolar proteinosis
- Disease ID
- DOID:12120
- Description
- "A lung disease that is characterized by abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange." [url:http\://en.wikipedia.org/wiki/Pulmonary_alveolar_proteinosis]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03007134 | Completed | Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial | July 2007 | July 2011 | |
| NCT00552461 | Completed | Phase 2 | Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis | January 2007 | December 2011 |
| NCT04516577 | Completed | Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis | January 1, 2020 | December 31, 2021 | |
| NCT02081092 | Completed | Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT | December 2013 | October 29, 2018 | |
| NCT03887169 | Completed | Phase 1/Phase 2 | Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. | September 16, 2019 | June 1, 2020 |
| NCT02468908 | Completed | Phase 1 | Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects | May 2015 | October 2015 |
| NCT04326036 | Enrolling by invitation | Early Phase 1 | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | March 25, 2020 | January 31, 2024 |
| NCT02852928 | Recruiting | European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank | December 2013 | December 2029 | |
| NCT02461615 | Recruiting | A National Registry For Pulmonary Alveolar Proteinosis | April 2015 | December 2030 | |
| NCT00030056 | Terminated | Phase 2 | GM-CSF in Patients With Pulmonary Alveolar Proteinosis | September 2001 | December 2005 |
| NCT03316651 | Unknown status | Phase 2 | Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis | August 2016 | December 2020 |
| NCT01983657 | Unknown status | Phase 2 | Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP. | January 2012 | October 2014 |
| NCT05300360 | Unknown status | Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis | August 16, 2021 | August 16, 2022 |
- Disase is a (Disease Ontology)
- DOID:850
- Cross Reference ID (Disease Ontology)
- ICD10CM:J84.01
- Cross Reference ID (Disease Ontology)
- ICD9CM:516.0
- Cross Reference ID (Disease Ontology)
- MESH:D011649
- Cross Reference ID (Disease Ontology)
- MIM:265120
- Cross Reference ID (Disease Ontology)
- MIM:300770
- Cross Reference ID (Disease Ontology)
- MIM:610913
- Cross Reference ID (Disease Ontology)
- MIM:610921
- Cross Reference ID (Disease Ontology)
- MIM:614370
- Cross Reference ID (Disease Ontology)
- NCI:C85037
- Cross Reference ID (Disease Ontology)
- ORDO:264675
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:10501004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0034050
- MedGen concept unique identifier (MedGen Concept name)
- C0034050
- MedGen unique identifier (MedGen Concept name)
- 18760
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011649